About
Eikonoklastes develops first-in-class gene therapies focusing on neurodegenerative diseases, initially targeting ALS by overexpressing Caveolin-1 to provide neuroprotection and improve neuronal function.
Explore Eikonoklastes's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.